'Cetuximab' presentation slideshows

Michael F Driscoll, MD Chief Fellow Medical Oncology / Hematology JGBCC University of Louisville

Update of 2010 American Society of Clinical Oncology (ASCO) Annual Meeting: Gastrointestinal Malignancies. Michael F Driscoll, MD Chief Fellow Medical Oncology / Hematology JGBCC University of Louisville. An Update on Gastrointestinal Cancer: Overview.

776 views • 58 slides

NCIC CTG CO.17 Abstract Authors

A trial of the National Cancer Institute of Canada Clinical Trials Group (NCIC CTG) and the Australasian Gastro-Intestinal Trials Group (AGITG).

573 views • 28 slides

CAIRO2 study of the Dutch Colorectal Cancer Group (DCCG)

Randomized phase III study of capecitabine, oxaliplatin and bevacizumab with or without cetuximab in advanced colorectal cancer. CAIRO2 study of the Dutch Colorectal Cancer Group (DCCG).

529 views • 27 slides

Adjuvant mFOLFOX6 +/- cetuximab in patients with K-ras mutant resected stage III colon cancer

Adjuvant mFOLFOX6 +/- cetuximab in patients with K-ras mutant resected stage III colon cancer. Richard Goldberg, Daniel Sargent, Stephen Thibodeau, Michelle Mahoney, Anthony Shields, Emily Chan, Sharlene Gill, Morton Kahlenberg, Suresh Nair, Steven Alberts.

432 views • 26 slides

Eric Van Cutsem*, M Nowacki, I Lang, S Cascinu, I Shchepotin, J Maurel,

454 views • 24 slides

ASCO 2008 MAIN HIGHLIGHTS

359 views • 15 slides

Authors: Presented by Alberts and Goldberg Analysis By Scott Berry Date posted: June 21 2010

Phase III Clinical Trial of FOLFOX with or without Cetuximab in Resected Stage 3 Colon Cancer: Cooperative Group Trial N0147 (NCCTG*, CALGB, ECOG, NCIC, NSABP, SWOG). Authors: Presented by Alberts and Goldberg Analysis By Scott Berry Date posted: June 21 2010.

269 views • 15 slides

Treatment for metastatic bladdercancer ( chemotherapy&radiotherapy ) Dr.Mina Tajvidi oncologist

Treatment for metastatic bladdercancer ( chemotherapy&radiotherapy ) Dr.Mina Tajvidi oncologist. 25 percent of patients will have muscle-invasive disease and either present with or later develop metastases The prognosis for patients with metastatic disease is poor

273 views • 13 slides

Baselga J et al. Proc SABCS 2010;Abstract PD01-01.

Cetuximab + Cisplatin in Estrogen Receptor-Negative, Progesterone Receptor-Negative, HER2-Negative (Triple-Negative) Metastatic Breast Cancer: Results of the Randomized Phase II BALI-1 Trial. Baselga J et al. Proc SABCS 2010;Abstract PD01-01. BALI-1 Trial Schema. Cetuximab/cisplatin (n = 115)

203 views • 8 slides

Cetuximab in the treatment of rheumatoid arthritis: a case report

Cetuximab in the treatment of rheumatoid arthritis: a case report Timothy Sullivan 1 ; John Deeken, MD 2 1 Georgetown University School of Medicine 2 Division of Hematology/Oncology, Georgetown University Hospital Georgetown University Background Discussion

1.08k views • 1 slides

Introduction

Genetic variants in immune response genes predict clinical outcome in mCRC patients treated with cetuximab-based therapy

105 views • 1 slides